PSMA PET/CT in diagnostiek en responsevaluatie in patiënten met primair gemetastaseerd prostaatkanker: Een overzicht van de impact op behandelbeslissingen

Rosemarijn H. Ettema; Wietske I. Luining; André N. Vis; Roderick C. N. van den Bergh

doi:10.1007/s13629-024-00420-w

PSMA PET/CT in diagnostiek en responsevaluatie in patiënten met primair gemetastaseerd prostaatkanker: Een overzicht van de impact op behandelbeslissingen

Translated title of the contribution: PSMA PET/CT in diagnostics and response evaluation in patients with primary metastasized prostate cancer: A review of the impact on treatment decisions

Rosemarijn H. Ettema^*
, Wietske I. Luining
, André N. Vis
, Roderick C. N. van den Bergh

^*Corresponding author for this work

St. Antonius Hospital
Utrecht University
afdeling Urologie, Prostaatkankernetwerk Nederland, Antoni van Leeuwenhoek, Amsterdam, Nederland
Electron Microscopy Center Amsterdam
Erasmus University Rotterdam

Research output: Contribution to journal › Article › Professional

34 Downloads (Pure)

Abstract

Prostate cancer is one of the most common cancers in man. Adequate staging is important in determining prognosis and guiding therapeutic decisions. The prostate specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has a higher diagnostic accuracy than conventional imaging, consisting of CT-thorax/abdomen and bone scintigraphy. This ensures better visualization of metastases and therefore changes the stage, usually to a higher stage, of prostate cancer at diagnosis. The impact of this stage shift on oncologic outcomes is unclear, however it hypothetically ensures better outcomes of patients diagnosed at the same stage. It is unclear which impact this stage shift should have on therapeutic decisions. In patients with metastatic prostate cancer PSMA PET/CT findings and treatment response on the PSMA PET/CT could predict the likelihood of successful treatment.

Translated title of the contribution	PSMA PET/CT in diagnostics and response evaluation in patients with primary metastasized prostate cancer: A review of the impact on treatment decisions
Original language	Dutch
Pages (from-to)	38-46
Number of pages	9
Journal	Tijdschrift voor urologie
Volume	14
Issue number	2-3
DOIs	https://doi.org/10.1007/s13629-024-00420-w
Publication status	Published - 1 Mar 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Metastatic
PSMA PET/CT
Prostate cancer
Response evaluation
Stage shift

Access to Document

10.1007/s13629-024-00420-w

Psma-petct-in-diagnostiek-en-responsevaluatie-in-patienten-met-primair-gemetastaseerd-prostaatkanker.pdfFinal published version, 906 KBLicence: CC BY

Cite this

@article{653b2595f4d54b2dbb31504d9f7876f3,

title = "PSMA PET/CT in diagnostiek en responsevaluatie in pati{\"e}nten met primair gemetastaseerd prostaatkanker: Een overzicht van de impact op behandelbeslissingen",

abstract = "Prostate cancer is one of the most common cancers in man. Adequate staging is important in determining prognosis and guiding therapeutic decisions. The prostate specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has a higher diagnostic accuracy than conventional imaging, consisting of CT-thorax/abdomen and bone scintigraphy. This ensures better visualization of metastases and therefore changes the stage, usually to a higher stage, of prostate cancer at diagnosis. The impact of this stage shift on oncologic outcomes is unclear, however it hypothetically ensures better outcomes of patients diagnosed at the same stage. It is unclear which impact this stage shift should have on therapeutic decisions. In patients with metastatic prostate cancer PSMA PET/CT findings and treatment response on the PSMA PET/CT could predict the likelihood of successful treatment.",

keywords = "Metastatic, PSMA PET/CT, Prostate cancer, Response evaluation, Stage shift",

author = "Ettema, \{Rosemarijn H.\} and Luining, \{Wietske I.\} and Vis, \{Andr{\'e} N.\} and \{van den Bergh\}, \{Roderick C. N.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = mar,

day = "1",

doi = "10.1007/s13629-024-00420-w",

language = "Dutch",

volume = "14",

pages = "38--46",

journal = "Tijdschrift voor urologie",

issn = "2211-3037",

publisher = "Springer Science + Business Media",

number = "2-3",

}

TY - JOUR

T1 - PSMA PET/CT in diagnostiek en responsevaluatie in patiënten met primair gemetastaseerd prostaatkanker

T2 - Een overzicht van de impact op behandelbeslissingen

AU - Ettema, Rosemarijn H.

AU - Luining, Wietske I.

AU - Vis, André N.

AU - van den Bergh, Roderick C. N.

PY - 2024/3/1

Y1 - 2024/3/1

N2 - Prostate cancer is one of the most common cancers in man. Adequate staging is important in determining prognosis and guiding therapeutic decisions. The prostate specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has a higher diagnostic accuracy than conventional imaging, consisting of CT-thorax/abdomen and bone scintigraphy. This ensures better visualization of metastases and therefore changes the stage, usually to a higher stage, of prostate cancer at diagnosis. The impact of this stage shift on oncologic outcomes is unclear, however it hypothetically ensures better outcomes of patients diagnosed at the same stage. It is unclear which impact this stage shift should have on therapeutic decisions. In patients with metastatic prostate cancer PSMA PET/CT findings and treatment response on the PSMA PET/CT could predict the likelihood of successful treatment.

AB - Prostate cancer is one of the most common cancers in man. Adequate staging is important in determining prognosis and guiding therapeutic decisions. The prostate specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has a higher diagnostic accuracy than conventional imaging, consisting of CT-thorax/abdomen and bone scintigraphy. This ensures better visualization of metastases and therefore changes the stage, usually to a higher stage, of prostate cancer at diagnosis. The impact of this stage shift on oncologic outcomes is unclear, however it hypothetically ensures better outcomes of patients diagnosed at the same stage. It is unclear which impact this stage shift should have on therapeutic decisions. In patients with metastatic prostate cancer PSMA PET/CT findings and treatment response on the PSMA PET/CT could predict the likelihood of successful treatment.

KW - Metastatic

KW - PSMA PET/CT

KW - Prostate cancer

KW - Response evaluation

KW - Stage shift

UR - https://www.scopus.com/pages/publications/85186446238

U2 - 10.1007/s13629-024-00420-w

DO - 10.1007/s13629-024-00420-w

M3 - Article

SN - 2211-3037

VL - 14

SP - 38

EP - 46

JO - Tijdschrift voor urologie

JF - Tijdschrift voor urologie

IS - 2-3

ER -

PSMA PET/CT in diagnostiek en responsevaluatie in patiënten met primair gemetastaseerd prostaatkanker: Een overzicht van de impact op behandelbeslissingen

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this